Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity

Thomas J Hayman1, Tamalee Kramp, Jenna Kahn

  • 1University of South Florida Morsani College of Medicine, Tampa, FL ; Radiation Oncology Branch, National Cancer Institute, Bethesda, MD.

Insights

The mechanistic target of rapamycin (mTOR) inhibitor PP242 enhances tumor cell radiosensitivity by delaying DNA repair. Unlike rapamycin, PP242 effectively inhibits both mTOR complexes, improving radiosensitization in vitro and in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Mechanistic target of rapamycin (mTOR) is crucial for gene translation and a potential radiosensitization target.
  • Rapamycin is an allosteric mTOR inhibitor, while PP242 is a competitive inhibitor.
  • Understanding differential mTOR inhibition is key for optimizing cancer therapy.

Purpose of the Study:

  • To compare the radiosensitizing effects of rapamycin and PP242.
  • To investigate the impact of these inhibitors on mTORC1 and mTORC2 activity.
  • To elucidate the mechanisms underlying PP242-mediated radiosensitization.

Main Methods:

  • Immunoblot analyses to assess mTORC1 and mTORC2 activity.
  • Clonogenic survival assays for in vitro radiosensitivity.
  • γH2AX foci analysis for DNA double-strand break repair.
  • In vivo studies using U251 xenografts in mice.

Main Results:

  • PP242 inhibited both mTORC1 and mTORC2, while rapamycin only partially inhibited mTORC1.
  • PP242 significantly increased radiosensitivity in tumor cell lines, both before and after irradiation.
  • PP242 delayed the repair of radiation-induced DNA double-strand breaks.
  • PP242 enhanced radiation-induced tumor growth delay in vivo without affecting normal fibroblasts.

Conclusions:

  • PP242 demonstrates superior radiosensitizing activity compared to rapamycin.
  • PP242 enhances tumor cell radiosensitivity by inhibiting DNA repair mechanisms.
  • PP242 shows promise as a radiosensitizer in preclinical cancer models.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...